Eli Lilly and Incyte Corporation announced that the FDA has approved OLUMIANT (baricitinib) for the treatment of adults with moderately-to-severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitor therapies. https://investor.lilly.com/news-releases/news-release-details/fda-approves-olumiantr-baricitinib-2-mg-tablets-treatment-adults Partner Therapeutics announced the recent FDA approval of Leukine for the treatment of adult and[…]